【4565】そーせいG 432

2017/12/03(日) 18:33:19.41

関連URL
http://www.sosei.com
http://www.heptares.com
http://www.jitsubo.com/jp
http://www.g7therapeutics.com
http://minatx.com
※前スレ
【4565】そーせいG 431
http://hayabusa9.2ch.net/test/read.cgi/livemarket1/1511147627/

VIPQ2_EXTDAT: checked:vvvvv:1000:512:----: EXT was configured

2017/12/15(金) 19:56:03.53

>>710
じゃあ、10800で売ってくれd(>_< )

2017/12/15(金) 21:39:27.89

こんな嘘ばかりのスレ取り消せ。
クソボケが、アホクソボケカスが。
根性無しのカスの集まりが。
どうせ何もできんのやろが？
カスはカスらしく黙っとらんかい！クソボケ！
何なんじゃアホが。この根性無しのクズが。
クソボケクズ。クズの集まりじゃねえか。
ポンコツのクソドアホが。ボンクラだろがてめえら。
はっきり言っといてやるよ。てめえらなんか、何一つ怖くないわ、
このクズ以下のポンコツボンクラが。

2017/12/15(金) 21:40:41.30

以上、ポンコツボンクラからの遺言でした。

2017/12/15(金) 22:20:34.73

17日にサイエンスZEROでクライオやるんだよね

2017/12/15(金) 23:59:07.18

>>705>>706
これって､､､

2017/12/16(土) 00:05:45.10

見ちゃダメ🙅‍♂️

2017/12/16(土) 02:10:13.35

ビットコイン→ラクオリアと来ていよいよ皆死んだか

2017/12/16(土) 06:03:02.90

※Heptares_HP Publications: Added, 2 Title. (12/15up)
・"Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.": (Nature Reviews Drug Discov. 2017 Sep;16(9):787-810.)
・"A monoclonal antibody raised against a thermo-stabilised β1-adrenoceptor interacts with extracellular loop 2 and acts
as a negative allosteric modulator of a sub-set of β1-adrenoceptors expressed in stable cell lines.": (Biochem Pharmacol. 2017 Nov 2;147:38-54.)

※HeptaresTL 5時間前：Ten years of advances in GPCR structure-based drug discovery: C&EN Looks back at 2007. (12/15)

2017/12/16(土) 06:03:56.72

※Journal Med: Current Information for Doctors: "Recommendation on the use of dual bronchodilation for majority symptomatic COPD patients". (12/15)
December 15, 2017
At the end of November, Novartis announced positive results from the FLASH study,
which evaluated the safety and efficacy of a direct conversion to patients with moderate to severe COPD from salmeterol / fluticasone to indacaterol / glycopyrronium (Ultibro Breezhaler).
The GOLD Report recommends the use of dual bronchodilation for majority symptomatic COPD patients and new data supports this recommendation.
The first randomized controlled trial FLASH for the direct conversion of LABA / ICS (salmeterol / fluticasone)
to Ultibro Breezhaler shows improved lung function in symptomatic patients with moderate to severe COPD.
Furthermore, German DACCORD Registry data also provide positive results for direct conversion to indacaterol / glycopyrronium from everyday practice.
・・・
These findings corroborate the current GOLD report,
which recommends the use of dual bronchodilation for the majority of symptomatic COPD patients regardless of the risk of exacerbation,
and limits the use of ICS-containing therapies to specific types of patients;
including patients who continue to exacerbate on LABA / LAMA treatment or who, e.g. have the findings of an asthma COPD overlap.
Evidence from everyday clinical practice:
Close to clinical practice, the open-label CRYSTAL study,
in which symptomatic patients with moderate COPD from their previous therapy (LABA + ICS, LABA / ICS, LABA, LAMA ) directly responded to indacaterol / Glycopyrronium were switched.
Here once again a superior improvement in lung function as well as a relief of respiratory distress (according to Transitional Dyspnoe Index) in the patients.
The data from the DACCOR Register come directly from everyday clinical practice in Germany.
Currently published results also support the recommendations of the GOLD report regarding escalation and de-escalation of COPD therapy.
For example, dual bronchodilation should be considered in patients who are symptomatic of bronchodilator monotherapy or LABA / ICS.
The data also support the use of LABA / LAMA as the preferred maintenance therapy for symptomatic COPD patients.
Furthermore, the analysis provides first practical experience for the de-escalation of LABA / LAMA / ICS to LABA / LAMA.
Overall, patients benefited from a one-year follow-up to exacerbations and health status (as measured by the COPD Assessment Test)
from a direct switch to dual bronchodilation with indacaterol / glycopyrronium.

2017/12/16(土) 08:18:15.03

楽天の貸株金利が上がって0.25%になったね
一番高いのはGMOの1％

2017/12/16(土) 13:06:08.50

今からでもこんなとこ損切ってサンバイオへ行けば損失取り戻せるよ
サンバは５０００円になる！

2017/12/16(土) 13:49:22.94

スレ削除の需要が高まってきてる

2017/12/16(土) 17:23:26.16

じゃあ来るな

2017/12/16(土) 21:57:56.13

ふと思ったんだけど
一時金って分割で毎年貰った方が良かったんじゃ？

2017/12/17(日) 07:31:23.86

次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares Approach Extends well Beyond our Growing Pipeline. UK be Relocating to the Cambridge Area in "July 2018."
・・・
※MiNA: "Innovate UK" Awards Grant: Exciting New Area of Research in Collaboration to "LGC LINK". Grant of up to Approximately 400,000 will Support. (11/2)
※Pluristem: Quarterly Report: Japan NewCo: The Parties have Agreed to Extend the Deadline to Enter into a Definitive Agreement Until December 31, 2017. (11/7)
※ALS Journal: "Metabotropic Glutamate Receptor Type 5 (mGlu5: HTL14242) Plays a Key Role in Glial Activation in the SOD1G93A Mouse Model of MND." (11/7)
※SOSEI：MiNA社、Boehringer Ingelheim社と線維性肝疾患の新治療法開発でライセンス契約締結。契約一時金や研究資金に加え、最大総額307百万ユーロのマイルストン受領予定。(11/8)
※SOSEI：レビー小体型認知症患者を対象とするHTL0018318の日本における臨床開発開始。提携契約を主要な認知症を追加承認取得するため改定。2018年Ph2 POC試験開始予定。(11/9)
※SOSEI第2四半期決算：研究開発費(94.6％は英国)増加。開発促進のための臨床開発並びにトランスレーショナル医療の拡大・拡張へ向けた取組み。毎年平均3品目化合物を臨床入り。(11/9)
※SOSEI第2四半期説明会資料：自社開発(自社での上市・販売)進捗 M1DLB, mGlu5。パイプライン開発進捗状況を更新。"AD4635のPh.1の進捗は良好、年内にP1bへの移行を予定"。(11/9up)
※AstraZeneca Q3 2017 Results, update Clinical Trials: AZD4635 (A2AR): Solid Tumours and Non-Small Cell Lung Cancer: Phase 1: "Data Anticipated: 2018". (11/9)
※米国特許出願(MiNA)：Albumin Production and Cell Proliferation. (11/9公開)
※国際特許出願(AstraZeneca)：Inhibitors of Protease-Activated Receptor-2. (Inventors: AstraZeneca R&D & Heptares). (11/16公開)
※LeadXpro: LeadXpro Scientists Chart the Future of Structure Based Drug Discovery. Serial Crystallography with the New XFEL Technology. A2A(Heptares) was Employed. (11/27)
※SOSEI：ウルティブロへ治療薬切り替え後のCOPD患者肺機能を有意に改善。Seretideから切り替えで肺機能が改善し、良好な忍容性を有する新データ(FLASH)が得られた。(11/28)
※ClinicalTrials: Study to Compare QVM149 and Free Triple Combination (salmeterol/ fluticasone+ tiotropium): Changed, Protocol: Similar→"Non-Inferior" (11/28update)
※Pluristem: Peer-Reviewed Article Published on PLX-PAD Cells’ Mechanism of Action to Restore Blood Flow in Ischemic Tissue. "Data Supports Advanced PLX-PAD Clinical." (11/29)
※ClinicalTrials: AZD4635, Phase 1, Estimated Study Completion Date Changed: "August 23, 2019", Number of Patients Changed: 51→"156". (11/29update)
※中国COPD新薬市場の進展：2018年には中国市場に参入予定。Ultibroも2017年5月に中国で上市申請を行い、来年後半以降、COPD市場全体に新たな変化が起こることが予想されます。(12/8)
※Pluristem: Granted Manufacturer Authorization and GMP Certification by Israel’s Ministry of Health. "The Approval Supports the Readiness of Manufacturing Capabilities." (12/12)
※中国COPDインダカテロール/グリコピロニウム化合物：CFDA薬物登録の進捗状況が「承認」に変更され、国内レビューおよび承認作業の完了に近づいています。(12/12)
・・・
※SOSEI株主通信第28期中間決算号：12月予定
※J.P.Morgan Healthcare Conference, San Francisco: "Attend: Heptares Executive Management Team (Business Development Event)" (2018/1/8-11)
・・・

2017/12/17(日) 07:32:29.78

※SOSEIの成長相場の動向：
Bloomberg：創薬ベンチャーのそーせいは買収を通じて業容を拡大し、株価は過去2年間で約300％上昇(2015/3/17終値2972→2017/3/17終値10750)。
・(2010/10/15※最安値_650、2010/5/22※最高値1545)
2010/12/30 (終値_1350) 売残高_2740 買残高_607100大納会2010 ・(2011/1/4大発会1292)
・(2011/3/15※最安値_693、2011/6/30※最高値1680)
2011/12/30 (終値_1271) 売残高_____0 買残高_518100大納会2011 ・(2012/1/4大発会1292)
・(2012/6/6※最安値_950、2012/9/7※最高値2967)
2012/12/21 (終値_2093) 売残高___100 買残高_653600 ・(2012/12/28大納会 2087) (2013/1/4大発会 2061)
・(2013/1/4※最安値2050、2013/5/7※最高値6100)
2013/12/20 (終値_4045) 売残高28500 買残高_833300 ・(2013/12/30大納会 4315) (2014/1/6大発会 4415)
・(2014/4/22※最安値1854、2014/9/8※最高値6000)
2014/12/19 (終値_4355) 売残高___700 買残高1691900 ・(2014/12/30大納会 4370) (2015/1/5大発会 4280)
・(2015/3/16※最安値2851、2015/6/19※最高値8780)
2015/12/25 (終値_9670) 売残高__7500 買残高2282200 ・(2015/12/30大納会 9950) (2016/1/4大発会10300)
・(2016/1/18※最安値3080、2016/5/9※最高値26180)
2016/12/30 (終値13450) 売残高___300 買残高2920000大納会2016 ・(2017/1/4大発会13720)
・(2017/9/6※最安値8590、2017/1/6※最高値14500)
2017/_9/_8 (終値_8700) 売残高__1900 買残高2037800
2017/11/17 (終値12190) 売残高__3100 買残高1532100
2017/12/_8 (終値10100) 売残高___900 買残高1849800
2017/12/15 (終値10870) 5日線乖離(+1.34%) 25日線乖離(-1.23％) 75日線乖離(+8.00％) 200日線乖離(-0.08％) (安値10820) ・(12/11安値10070)

※Technical Analysis Charts:
ttps://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=805&Height=650&Cycle=WEEK1&Duration=120&TopMargin=10&Render=Candle&ShowName=0&Company=4Traders_us

更なる成長の黎明期、上抜け圏にて、強気相場解除後の時間軸での調整は順調推移。笑。
時間軸調整にて、信用組の振るいも順調に推移し、今回も調整終盤の拾い場を経て、予定通りに面白くなりましたね。笑。
中長期の成長戦略も着実に進み、次なる展開・進捗が楽しみですね。笑。

2017/12/17(日) 08:09:45.01

ヘンダーソン博士の講演会行きたい奴は現物買っとけよ

2017/12/17(日) 09:25:05.58

いらねえよ
どうせわかってもいないのに、わかったつもりの受け売りの知識で行った感想書き込まれるんだな

2017/12/17(日) 09:58:21.92

来年から１２月期決算になるはずなのに四季報に反映されていない

2017/12/17(日) 17:52:28.47

そーせいスレ最終回でございます
次の大相場までごきげんよう

2017/12/17(日) 18:01:05.00

Pluristem:
※Pluristem: Pluristem and Sosei CVC to Establish a New Corporation for the Commercialization of PLX-PAD in Japan. (2016/12/20)
※Pluristem: Pluristem’s Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDA. (1/10)
※Pluristem: Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval. (1/17)
※Pluristem: Pluristem and Sosei CVC Advancing Towards Finalizing Joint Venture forthe Commercialization of PLX-PAD in Japan. (3/30)
※Pluristem Presentation: "Closing JV deal with Sosei: H2 2017", "Japan pivotal study initiation: H1 2018" (Change, 9/17up)
(・"Extend the deadline to enter into a definitive agreement by 2017/12/31" SoseiCVC Agreed 8/15. As a next step, submit a Clinical Trial notification to the PMDA.)
※Pluristem: U.S. FDA Grants Fast Track Designation to PLX-PAD for the Treatment of CLI. (In Japan, accepted accelerated regulatory pathway.) (9/18)
※Pluristem: Presentation October: ttp://www.pluristem.com/wp-content/uploads/2016/04/Pluristem-Investor-deck-29.10.2017.pdf (10/29up)
(・Pluristem: Video- Japanese: ttps://www.youtube.com/watch?v=kw_JP6FixMI (2015/02/10up))
(・Pluristem: Stem Cell Meeting on the Mesa 2015: ttps://www.youtube.com/watch?v=ON82ZQa-pfg (2015/10/22up))
(・Pluristem: Advanced Therapies Investor Day: ttps://www.youtube.com/watch?v=bVOOuyLvBbM&t (2015/11/30up))
(・Pluristem: Cell Gene Meeting on the Mesa 2016: ttps://www.youtube.com/watch?v=wMN4SoVpPSw (2016/10/24up))
(・Pluristem: Cell Gene Investor Day: ttps://www.youtube.com/watch?v=BlsEDBrOEbw (5/4up))
(・Pluristem: PLX-PAD Instructions, Study PLX-CLI-03(NCT03006770): ttps://www.youtube.com/watch?v=h_t3oDhEkIg&t (5/14up))
(・Pluristem: Zami Aberman - NHPs Study Results for ARS: ttps://www.youtube.com/watch?v=i4nRUESNAXk (5/18up))
(・Pluristem: Placental Cell Therapy: ttps://www.youtube.com/watch?v=1A3zI68uWFY (6/15up))
(・Pluristem: Cell Therapy – The Next Generation of Biological Therapeutic Products: ttps://www.youtube.com/watch?v=DXrqyLm-YwM (6/24up))
(・Pluristem: PLX-PAD as a Treatment for Peripheral Artery Disease- CLI - Unmet Needs: ttps://www.youtube.com/watch?v=niOhN-fEQmU&t (6/27up))
(・Pluristem: The Solution for Nuclear Disaster: ttps://www.youtube.com/watch?v=larWZ1dRxMA (7/20up))
(・Pluristem: Cell Therapy- The Answer for Aging and Longevity: ttps://www.youtube.com/watch?v=scxgz3BOITE (7/20up))
(・Pluristem: Cell Therapy to treat Acute Radiation Syndrome: ttps://www.youtube.com/watch?v=jyD-oXHUwqQ&t (8/27up))
(・Pluristem: US Military Testing Radiation Exposure Drug- CNN: ttps://www.youtube.com/watch?v=N1jjf5s7iHY (9/2up))
(・Pluristem: Introduction with Pluristem: ttps://www.youtube.com/watch?v=q79hgJQgRps (10/4up))
(・Pluristem: Instructions For IP Use in Clinical Trial PLX-PAD 1204-01(NCT01679990): ttps://www.youtube.com/watch?v=1kMtv1mU8n0 (11/2up))
※Pluristem: Innovative Technology, Cell Therapy Products and a Potentially Answer for Radiation Exposure: ttps://www.youtube.com/watch?v=yqLDlikcG_I (11/23up)
※Pluristem: Peer-Reviewed Article Published on PLX-PAD Cells’ Mechanism of Action to Restore Blood Flow in Ischemic Tissue. "Data Supports Advanced PLX-PAD Clinical." (11/29)
※Pluristem: The Jerusalem Post Diplomatic Conference: Presents at Cure for Radiation Catastrophes. ttps://www.youtube.com/watch?v=ZiEj_pnmc38 (12/6)
※Pluristem: Granted Manufacturer Authorization and GMP Certification by Israel’s Ministry of Health. "The Approval Supports the Readiness of Manufacturing Capabilities." (12/12)
・・・